发明申请
- 专利标题: CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS
- 专利标题(中): 重要的免疫缺陷病毒治疗人类癌症
-
申请号: US13570032申请日: 2012-08-08
-
公开(公告)号: US20120302732A1公开(公告)日: 2012-11-29
- 发明人: Michael Jensen
- 申请人: Michael Jensen
- 申请人地址: US CA Duarte
- 专利权人: CITY OF HOPE
- 当前专利权人: CITY OF HOPE
- 当前专利权人地址: US CA Duarte
- 主分类号: C07K14/725
- IPC分类号: C07K14/725 ; C07H21/04 ; C12N15/63
摘要:
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.
公开/授权文献
- US08497118B2 Chimeric immunoreceptor useful in treating human cancers 公开/授权日:2013-07-30